Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

Summary

This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for recurrent or refractory central nervous system tumors for which there are no curative options. Patients will also be followed for safety, time to progression, event free survival and overall survival

Timeline

Start

2017-05-18

Primary completion

2020-08-25

Completion

2020-08-25

Outcome

Outcome not reported

Stopped (Enrollment): “Failure to meet accrual goals.”

Drugs

Indications